Free Trial
OTCMKTS:TBIO

Telesis Bio Q1 2024 Earnings Results & Report

Telesis Bio logo
$0.01 0.00 (0.00%)
As of 11/9/2026 03:24 PM Eastern

Telesis Bio missed analyst revenue expectations in its Q1 2024 results, released May 9, 2024. The company reported EPS of -$99.28, while revenue of $3.44 million fell short of the $6.90 million estimate by $3.46 million.

Earnings Announcement Details

Quarter
Q1 2024
Report Date

Telesis Bio EPS Results

Actual EPS
-$99.28
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Telesis Bio Revenue Results

Actual Revenue
$3.44 million
Expected Revenue
$6.90 million
Beat/Miss
Missed by -$3.46 million
YoY Revenue Growth
N/A

Upcoming Earnings

Telesis Bio's next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Conference Call Resources

Telesis Bio Q1 2024 Earnings FAQ

Telesis Bio (OTCMKTS:TBIO) reported earnings of -$99.28 per share for Q1 2024. The report was announced on Thursday, May 9, 2024.

Telesis Bio reported revenue of $3.44 million for Q1 2024, against a consensus estimate of $6.90 million.

Telesis Bio's next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Telesis Bio on the company's earnings history page.

Telesis Bio Earnings Headlines

Telesis Bio, Inc. Common Stock (TBIO)
Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
Telesis Bio Inc.
See More Telesis Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Telesis Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telesis Bio and other key companies, straight to your email.

About Telesis Bio

Telesis Bio (OTCMKTS:TBIO) develops automated synthetic biology systems designed to help researchers create and test biological molecules more efficiently. Its technology is intended to streamline the design-build-test process by automating tasks that traditionally require multiple manual laboratory steps.

The company’s primary products include the BioXp automated benchtop platforms and related consumables, software, and application-specific kits. These systems support the on-demand synthesis and assembly of DNA, messenger RNA and other biological constructs for applications such as gene and cell therapy research, vaccine development, protein engineering, diagnostics and synthetic biology.

Telesis Bio was formerly known as Codex DNA and changed its corporate name in 2023. The company markets its products to biotechnology and pharmaceutical companies, academic and government research institutions, and other life sciences organizations. Its platform is designed for use by customers in research and development laboratories in the United States and international markets.

View Telesis Bio Profile